Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Investisbio Out-Licenses KRAS G12C Inhibitor to Sino Biopharm Subsidiary

publication date: Aug 8, 2023

Shanghai Investisbio out-licensed China rights for its KRAS G12C inhibitor to Nanjing Chia-Tai Tianqing Pharma, a division of Sino Biopharm. D-1553 is aimed at treating non-small cell lung cancer, colorectal cancer and other cancers with the KRAS G12C mutation. Investisbio says D-1553 is approved to start a China Phase II trial for NSCLC patients with the mutation. Financial details of the agreement were not disclosed, but Chia-Tai Tianqing is eligible to receive royalties on ex-China D-1553 revenues based on data sharing from its China trials. More details....

Stock Symbol: (SHA: 688382)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital